Gain Therapeutics
Price & Volume
Stats
See moreOpen | $2.70 |
Previous Close | $2.66 |
Day Range | $2.70-$2.83 |
52W Range | $1.41-$3.06 |
Market Cap | $96.4M |
Shares Short | 910,705 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$8.9M |
Diluted EPS | -$0.61 |
News
See moreYahoo Finance • last month
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Yahoo Finance • 2 months ago
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
Yahoo Finance • 2 months ago
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Yahoo Finance • 2 months ago
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
About
CEO | Mr. Gene Mack M.B.A. |
Address | 4800 Montgomery Lane, Bethesda, MD, United States, 20814 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 23 |
